1. Clinically relevant concentrations of lidocaine inhibit tumor angiogenesis through suppressing VEGF/VEGFR2 signaling

   • Jin Gao
   • Huimin Hu
   • Xuesong Wang

   Original Article 18 March 2019 Pages: 1007 - 1015

   

2. d,l-Methadone does not improve radio- and chemotherapy in glioblastoma in vitro

   • Henry Oppermann
   • Martina Matusova
   • Frank Gaunitz

   Original Article 19 March 2019 Pages: 1017 - 1024

   

3. A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors

   • Niharika B. Mettu
   • Donna Niedzwiecki
   • Hope Uronis

   Original Article 20 March 2019 Pages: 1025 - 1035

   

4. Placental growth factor is a predictive biomarker for ramucirumab treatment in advanced gastric cancer

   • Makoto Natsume
   • Takaya Shimura
   • Hiromi Kataoka

   Original Article 21 March 2019 Pages: 1037 - 1046

   

5. Outcomes of preoperative S-1 and docetaxel combination chemotherapy in patients with locally advanced gastric cancer

   • Takashi Kosaka
   • Hirotoshi Akiyama
   • Itaru Endo

   Original Article 25 March 2019 Pages: 1047 - 1055

   

6. First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinoma

   • Christophe Massard
   • Jean-Charles Soria
   • Haby Henary

   Original Article 26 March 2019 Pages: 1057 - 1063

   

7. LncRNA SNHG16 sponges miR-98-5p to regulate cellular processes in osteosarcoma

   • Shian Liao
   • Shuxing Xing
   • Yanhui Ma

   Original Article 28 March 2019 Pages: 1065 - 1074

   

8. The combination of olaratumab with gemcitabine and docetaxel arrests a chemotherapy-resistant undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft mouse model

   • Takashi Higuchi
   • Kentaro Miyake
   • Robert M. Hoffman

   Original Article 30 March 2019 Pages: 1075 - 1082

   

9. Apatinib for chemotherapy-refractory extensive-stage SCLC: a retrospective study

   • Hui Li
   • Jian Zeng
   • Wei Hong

   Original Article 01 April 2019 Pages: 1083 - 1090

   

10. Comparison of palonosetron and granisetron in triplet antiemetic therapy in nonmetastatic breast cancer patients receiving high emetogenic chemotherapy: a multicenter, prospective, and observational study

    • Murat Araz
    • Mustafa Karaagac
    • Mehmet Artac

    Original Article 08 April 2019 Pages: 1091 - 1097

    

11. De-escalated neoadjuvant therapy with nanoparticle albumin-bound paclitaxel and trastuzumab for low-risk pure HER2 breast cancer

    • Satoru Tanaka
    • Nobuki Matsunami
    • Mitsuhiko Iwamoto

    Original Article 08 April 2019 Pages: 1099 - 1104

12. Equipotent doses of daunorubicin and idarubicin for AML: a meta-analysis of clinical trials versus in vitro estimation

    • Sunil Adige
    • Rena G. Lapidus
    • Ashkan Emadi

    Original Article 09 April 2019 Pages: 1105 - 1112

    

13. Investigation of anti-tumor effect of doxorubicin-loaded human serum albumin nanoparticles prepared by a desolvation technique

    • Kotaro Kimura
    • Keishi Yamasaki
    • Masaki Otagiri

    Original Article 10 April 2019 Pages: 1113 - 1120

    

14. Docetaxel, cisplatin, and 5-fluorouracil combination chemoradiotherapy for patients with cervical esophageal cancer: a single-center retrospective study

    • Makoto Sakai
    • Makoto Sohda
    • Ken Shirabe

    Original Article 09 April 2019 Pages: 1121 - 1126

    

15. Rabeprazole intake does not affect systemic exposure to capecitabine and its metabolites, 5′-deoxy-5-fluorocytidine, 5′-deoxy-5-fluorouridine, and 5-fluorouracil

    • Masae Sekido
    • Ken-ichi Fujita
    • Yasutsuna Sasaki

    Original Article 09 April 2019 Pages: 1127 - 1135

    

16. Comparison of two different carboplatin and weekly paclitaxel schedule in elderly advanced non-small cell lung cancer patients

    • Derya Kıvrak Salim
    • Tuğba Akın Telli
    • Perran Fulden Yumuk

    Original Article 09 April 2019 Pages: 1137 - 1145

    

17. Pharmacokinetic and exploratory exposure–response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study

    • Whitney P. Kirschbrown
    • Matts Kågedal
    • Amit Garg

    Original Article Open access 11 April 2019 Pages: 1147 - 1158

    

18. Modeling long-term tumor growth and kill after combinations of radiation and radiosensitizing agents

    • Tim Cardilin
    • Joachim Almquist
    • Johan Gabrielsson

    Original Article Open access 11 April 2019 Pages: 1159 - 1173

    

19. Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial

    • Fernando Rivera
    • C. Romero
    • C. López

    Clinical Trial Report Open access 29 March 2019 Pages: 1175 - 1181

    

20. Inactivation of apaziquone by haematuria: implications for the design of phase III clinical trials against non-muscle invasive bladder cancer

    • Roger M. Phillips
    • Paul M. Loadman
    • Guru Reddy

    Short Communication Open access 13 March 2019 Pages: 1183 - 1189

    

21. FLAG vs FLAG-IDA: outcomes in relapsed/refractory acute leukemias

    • Muhammad Umer Farooq
    • Fahad Mushtaq
    • Muhammad Ayaz Mir

    Short Communication 13 February 2019 Pages: 1191 - 1193

    

22. Short-time use of crizotinib as neoadjuvant in ALK-positive non-small cell lung carcinoma can be a chance for resectability

    • Saadettin Kilickap
    • Sevgen Onder
    • Aysegul Uner

    Letter to the Editor 12 March 2019 Pages: 1195 - 1196